Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle Post published:June 23, 2025 Post category:Analysis/News
Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy for PTSD in First-of-its-Kind Program Post published:June 18, 2025 Post category:Analysis/News/Pα+
Breaking: atai Moves to Acquire Beckley, If Phase 2b 5-MeO-DMT Data Delivers Post published:June 2, 2025 Post category:Analysis/News/Pα+
Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine Trials Post published:May 28, 2025 Post category:Analysis/News
Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder Study Post published:May 27, 2025 Post category:Analysis/News/Pα+
Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics Czar Post published:May 24, 2025 Post category:Analysis/News/Pα+
FDA’s Makary Hints at Faster Reviews for Psychedelic Therapies Post published:May 19, 2025 Post category:Analysis/News/Pα+
The Interdisciplinary Annotated Psychedelic Research Bibliography of 2024 Post published:May 14, 2025 Post category:2023 Year in Review/Analysis
Spring 2025 Psychedelic Policy Update: Bills Hang in the Balance as Legislative Sessions Wind Down Post published:May 13, 2025 Post category:Analysis/News/Pα+
Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2) Post published:May 12, 2025 Post category:Analysis/News